Who Paid My Doc
Lyfgenia
Drug sickle-cell
NDC 73554-1111-1
General payments
$178,428
Research payments
$3,889,544
Through program year 2024, $178,428 in general payments and $3,889,544 in research payments were reported against Lyfgenia (sickle-cell).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $147,559 | 134 |
| 2024 | Research | $2,483,329 | 94 |
| 2023 | General | $30,870 | 14 |
| 2023 | Research | $1,406,215 | 94 |
Breakdown
The top 5 of 86 recipients; each share is of general payments naming this product in 2024.
The top 5 of 21 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 22 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
148 general · 188 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.